A
AI Medical Service
AI-powered diagnostic support for gastrointestinal endoscopy
About AI Medical Service
AI Medical Service Inc. (AIM) is a Japanese medical technology company founded in September 2017 by Dr. Tomohiro Tada, a gastroenterologist and endoscopist. The company was established to address the challenge of missed cancer diagnoses during endoscopic examinations, with reports indicating that a significant percentage of early-stage gastrointestinal (GI) cancers are overlooked. Dr. Tada, who has performed over 20,000 endoscopic procedures, founded the company based on his clinical experience and desire to reduce these diagnostic oversights.
The core of AIM's business is the development and distribution of artificial intelligence-based software designed to assist physicians in real-time during endoscopic procedures. This software analyzes images from the endoscope to detect and highlight suspicious lesions that may be cancerous, covering the esophagus, stomach, and colon. The technology is built on deep learning algorithms trained with extensive datasets of endoscopic images from joint research collaborations with over 100 medical institutions. The company's flagship product, "gastroAI-model G," is a diagnostic support system for gastric cancer that received manufacturing and marketing approval in Japan. AIM operates on a software-as-a-service (SaaS) business model, providing its latest software to medical institutions through annual subscription agreements.
Since its founding, AI Medical Service has achieved several key milestones. In November 2019, the company received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its gastric cancer diagnostic AI. The company has also secured regulatory approvals for its products in multiple countries, including Japan, Singapore, and Thailand. AIM has actively pursued global expansion, establishing joint research agreements with institutions such as Stanford Medicine in the U.S., Mahidol University in Thailand, and The Chinese University of Hong Kong. The company has raised significant capital to fund its research, clinical trials, and global expansion, with total funding reaching approximately $115 million over several rounds. In June 2025, to accelerate its commercialization phase, Dr. Tada transitioned to the role of Chairman, and Yasushi Takigawa, a seasoned executive with experience at Boston Scientific and other medical device companies, was appointed as President and Representative Director.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 45
- Open positions
- None listed
- Dealroom signal
- 65.2/100
- Industry
- Health
- Sub-industry
- Health Platform
- Sector
- Analytics, Oncology, Core AI, Tech for Medical Professionals, AI for medical imaging, AI Applications, DT and LS, science-based
- Technology
- Artificial Intelligence, Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Apr 2022 | $63M | $252M | Globis Capital Partners · SoftBank · Incubate Fund · World Innovation Lab | ↗ |
| SUPPORT PROGRAMOther financing | Jan 2021 | $0 | — | J-Startup | — |
Growth signals
Latest recorded traffic for AI Medical Service is 15K monthly website visits, up 50% over the last three months. AI Medical Service's team declined 4.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
AI Medical Service in the Tokyo ecosystem
The AI Medical Service office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Incubate Fund
World Innovation Lab
Globis Capital Partners
Sony Innovation Fund
Series B and later1 investor entered at this stage
Other known investors2 additional known investors
Google for Startups Accelerator
J-Startup
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AI Medical Service on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AI Medical Service’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









